Degenerative Disc Disease, Spondylolisthesis, Stenosis
Conditions
Keywords
Primary lumbar fusion, Demineralized Bone Matrix, DBM, Optecure, Allograft, Autograft, Lumbar fusion, Interbody fusion, Instrumented fusion, Non-instrumented fusion, Exactech, Spinal fusion
Brief summary
The purpose of this study is to compare Optecure™ as an autograft extender (treatment) to autograft alone (control) in patients undergoing 1 or 2 level fusion of the lumbar spine(one level is defined as two adjacent vertebrae), L2 and below. The primary endpoint will be the assessment of fusion by evaluation of x-rays taken following surgery at each visit. The x-ray evaluation will be conducted by a radiologist who is blinded to the type of treatment each patient has received. Subjects will be seen at 6 weeks, 3 months, 6 months, 12 months, and 24 months postoperative (post-op). Questionnaires and x-rays will be completed at each visit and a computed tomography (CT) scan will be taken at the 12 month visit(and used to aid in assessment of bridging bone, where appropriate).
Detailed description
Autograft (bone taken from one part of the body and placed in another site on the same individual) has long been considered the gold standard for lumbar spine fusion procedures. Unfortunately, there are complications involved with autograft harvest such as donor site morbidity, increased operating time, and limited supply. Therefore, the use of allograft (bone taken from one body and placed into another individual) as a graft extender has become an acceptable practice, especially in fusions of more than one level where larger quantities of graft material are needed. In this study, comparisons will be made between patients who are randomized to having fusion with an allograft material (Optecure, Exactech, Inc.) mixed with an autograft to those patients who are randomized to having fusion with autograft alone.
Interventions
PROCEDUREPosterior Lateral Fusion (PLF)
Posterior lateral fusion (PLF) of the lumbar spine
Anterior lumbar interbody fusion (ALIF)
Transforaminal lumbar interbody fusion (TLIF)
Posterior lumbar interbody fusion (PLIF)
PROCEDUREExtreme lateral interbody fusion (XLIF)
Extreme lateral interbody fusion (XLIF)
Sponsors
Exactech
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
ALL
Age
21 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patient is indicated for primary lumbar fusion of 1 or 2 segments, L2 to S1 * Patient is willing to be blindly randomized to treatment or control and remain blinded for 2 years of follow-up * Patient is at least twenty-one (21) years of age * Patient is expected to survive at least 2 years beyond surgery * Patient is willing to participate by complying with pre- and postoperative visit requirements, including: completion of questionnaires, functional performance tests, and radiographs/CT scan * Patient is willing and able to review and sign a study Informed Consent form
Exclusion criteria
* Patient has a mental or physical condition that would invalidate evaluation results * Patient is pregnant * Patient is a prisoner * Patient has a systemic infection or infection at the proposed surgical site * Patient has osteopenia, osteoporosis, or osteomalacia to a degree that spinal instrumentation would be contraindicated * Patient has a disease of bone metabolism * Patient is undergoing chemotherapy or radiation treatment * Patient is currently involved in a study of another product for a similar purpose * Patient requires post-op management with nonsteroidal anti-inflammatory drugs (NSAIDs)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Radiographic evidence of fusion on x-rays taken at each post-op visit | Immediate post-op, 6-week, 3-month, 6-month, 1-year, 2-year |
Secondary
| Measure | Time frame |
|---|---|
| Oswestry Disability Index (ODI) completed at each visit | pre-operative, 6-week, 3-month, 6-month, 1-year, 2-year |
| SF-12 patient health surveys completed at each visit | Pre-operative, 6-week, 3-month, 6-month, 1-year, 2-year |
| Perceived pain noted on visual analog scales (VAS) at each visit | Pre-operative, 6-week, 3-month, 6-month, 1-year, 2-year |
Countries
United States
Outcome results
None listed